Genome-wide genotyping data are increasingly available for pharmacogenetic association studies, but application of these data for development of prediction models is limited. Prediction methods, such as elastic net regularization, have recently been applied to genetic studies but only limitedly to pharmacogenetic outcomes. An elastic net was applied to a pharmacogenetic study of progression-free survival (PFS) of 468 patients with advanced breast cancer in a clinical trial of paclitaxel, nab-paclitaxel, and ixabepilone. A final model included 13 single nucleotide polymorphisms (SNPs) in addition to clinical covariates (prior taxane status, hormone receptor status, disease-free interval, and presence of visceral metastases) with an area under the curve (AUC) integrated over time of 0.81, an increase compared to an AUC of 0.64 for a model with clinical covariates alone. This model may be of value in predicting PFS with microtubule targeting agents and may inform reverse translational studies to understand differential response to these drugs.
but this can be difficult for pharmacogenetic phenotypes, in which different drugs, drug combinations, or patient populations are under study. [11] [12] [13] Genome-wide data for pharmacogenetic phenotypes have not been extensively used for developing models that will predict the treatment response, often involving many single nucleotide polymorphisms (SNPs) simultaneously, regardless of their statistical association with the outcome. 14, 15 In recent years, there have been an increasing number of genetic analyses using regularized regression methods, such as elastic net or least absolute shrinkage and selection operator (LASSO) regression, [14] [15] [16] [17] Support Vector Machine algorithms, 18 and random forest regression 19 for developing a model predicting outcome using multiple SNPs. Regularized regression methods have been applied to cell line studies for drug response, [20] [21] [22] [23] and there have been recent applications of such analyses in the prediction of duloxetine response. 24 These models can improve prediction error and reduce overfitting as well as perform variable selection. 18, 25, 26 Although this type of modeling will not allow for inferences to be made regarding the strength of association between a SNP and the outcome of interest, a model can be developed that can aid in prediction. Here, we apply an elastic net model to a study focused on predicting progression-free survival (PFS) in patients with advanced breast cancer in a clinical trial of microtubule targeting agents. 27 
RESULTS
The clinical characteristics of the 468 genetic European patients in the primary analysis closely resembled the original trial population (see Table 1 ). The median follow-up time in this European discovery sample was 32.2 months, and there were a total of 406 observed disease progression events or deaths. A standard genome-wide association study (GWAS) was performed initially, using a Cox proportional hazards model to assess the effect of each SNP on PFS, stratified by treatment arm, and controlling for previously identified clinical covariates. 27 For a significance threshold of 5E-8, no significant associations are detected. Therefore, an approach leveraging the strength of multiple SNPs collectively was applied to develop a prediction model.
Across the 10 models from the initial elastic net analyses, a median of 312 SNPs were retained (range: 263-340). The hazard ratios (HRs) ranged from 0.72−1.36, but the majority of SNPs remaining in each model had HRs between 0.95 and 1.05 (see Figure 1 ). Applying each model to the corresponding test set, the median area under the curve (AUC) collapsed across time is 0.78 (range: 0.75-0.81). A model with only clinical covariates results in a median AUC of 0.62 (range: 0.60-0.65). Comparing across models, only a few SNPs were selected in all training sets. There are 832 SNPs that were selected in just a single model, but only 13 SNPs were selected in all 10 (see Figure 2 ). Although some SNPs with larger effect sizes are selected only once or twice, these are rare exceptions. In general, the more often a SNP is selected, the less likely it is to be driven by only a few samples and the more likely it is to have a large effect size (see Figure 2) .
A final model for prediction of PFS was created among all genetic European samples with the clinical covariates and only the 13 SNPs selected by all 10 initial models (see Table 2 ). For a validation set of 130 non-European samples, AUC was calculated across varying time points. The median follow-up time in this nonEuropean validation sample was 24.1 months, and there were a total of 113 observed disease progression events or deaths. A model with only clinical covariates was compared to a model with clinical covariates and the 13 SNPs (see Figure 3 ). Across the time period from 0−50 months, the model with only clinical covariates had an integrated AUC of 0.64 with a 95% confidence interval (CI) of 0.60-0.67. Addition of the 13 SNPs to the model yielded an integrated AUC of 0.81 (95% CI: 0.77-0.83). Across 10,000 simulations of equivalent models with 13 randomly selected SNPs, only 2,934 resulted in models retaining SNP covariates, none of which performed as well as our final model (median integrated AUC: 0.64; range: 0.63-0.70).
Because the elastic net was used to construct our final model, many model diagnostics are not feasible. Using a standard Cox proportional hazard regression in lieu of the actual final model leads to similar effect sizes for all covariates. The proportionality assumption for all variables was tested and verified. Additionally, a deviance-like test was performed, and there was a significant (P < 2.2E-16) reduction in model log-likelihood with the addition of the 13 SNPs compared with the model with clinical covariates alone.
DISCUSSION
Here, an elastic net approach was applied to develop a prediction model of PFS in a clinical trial of paclitaxel, nab-paclitaxel, and ixabepilone in 468 genotyped patients with advanced breast cancer with European ancestry. The model was then validated in 130 genotyped patients with advanced breast cancer with non-European ancestry. Elastic net models reduce overfitting and perform variable selection, resulting in improved prediction error. Including genetic covariates improves the predictive ability (AUC = 0.81) compared with a model using only clinical covariates (AUC = 0.64). Additionally, the SNP effect sizes are comparable to or greater than those of the clinical covariates. The final model also validates the importance of controlling for multiple SNPs simultaneously, as it allows for inclusion of SNPs that are associated with both improved and worsened clinical outcome (see Table 2 ).
One limitation of this approach includes computational resources. Although it is theoretically possible to include all SNPs genome-wide in the elastic net model, this is computationally burdensome. In order to reduce the computational load, only the top 1,000 SNPs from a univariate analysis were used in the elastic net model. Whereas this ensures that the SNPs with the smallest P values are included in the elastic net model, SNPs with larger P values but important for prediction may be omitted from the final model. Screening based on univariate effect size rather than P value was considered, but the limited range of effect sizes led to more SNPs with lower effect sizes and fewer SNPs selected by all initial models. We also investigated the ideal number of SNPs to use in the elastic net and concluded that, for our data, 1,000 SNPs is optimal. Inclusion of < 1,000 SNPs led to a model that did not improve integrated AUC as much as the final model presented above, and > 1,000 SNPs had a negative effect on results, likely due to the addition of noise, hindering model optimization. Additionally, some of the SNPs remaining in the model have different minor allele frequencies in the European training and non-European validation sets (see Table 2 ), which could potentially affect the prediction accuracy. However, the increase in AUC observed with the non-European samples suggests this prediction model is robust to population differences and genotype frequencies. Caveats of this approach are that elastic net methods require complete data, and, for the Cox proportional hazards implementation, it is not possible to stratify on a predictor. Finally, application of this method to other data may require optimization of the elastic net constraint parameter α.
The Cancer and Leukemia Group B (CALGB) 40502 tested whether newer microtubule-targeting agents showed improved PFS and/or toxicity in patients with locally recurrent or metastatic breast cancer. The conclusion was that ixabepilone was inferior and nab-paclitaxel was not superior, with a trend toward inferiority, compared with paclitaxel. Toxicity was also increased in experimental arms. Because the two alternative therapies will not replace the standard-of-care paclitaxel, the prediction model developed here will have limited clinical utility in making treatment decisions between these three options. However, there may be some utility in making a prediction estimate for PFS in this setting when treated with paclitaxel. Pharmacogenetic findings can also inform regarding the underlying mechanisms of drug response. Of the 13 SNPs remaining in the final model, several are annotated to genes that are plausibly related to the pharmacology of microtubule targeting agents, including a kinesin family member and genes involved in mitogenactivated protein kinase signaling (see Table 2 ). The focus in prediction modeling is not on determining direct associations between a single SNP and the outcome of interest but, rather, on the collective predictive ability of multiple SNPs simultaneously. However, these genomic regions may be good candidates for further exploration in clinical and molecular studies. Whether these variants or genomic regions might be interrogated for their contribution to the poor response in the treatment arms of CALGB 40502 would require further study. These same variables could also be the focus of reverse-translational studies to understand microtubule-targeting agents.
METHODS
Patients and drug response phenotype Data collection was conducted by the Alliance Statistics and Data Center. Genotype and phenotype data were collected from CALGB 40502 (NCT00785291), a phase III randomized three-arm study comparing nanoparticle albumin-bound (nab) paclitaxel or ixabepilone to paclitaxel (all given with bevacizumab) as first-line therapy for patients with advanced breast cancer. Trial design and outcome have been previously described. 27 CALGB is now part of the Alliance for Clinical Trials in Oncology. PFS was the primary end point. The analyses described here tested whether incorporating both clinical risk variables and genetic risk alleles provides an improved prediction model for PFS.
Genotyping and quality control
Genotyping and analysis of existing samples was approved by the National Cancer Institute Adult Central Institutional Review Board and by the Institutional Review Board at the University of California San Francisco. All participants provided written informed consent for pharmacogenetic sample procurement and analysis, and all studies were conducted in accordance with recognized ethical guidelines. From the 799 patients randomized to the parent study, 633 consented to the pharmacogenetic substudy and had DNA available for genotyping (see Figure 4) . DNA samples were genotyped using the Illumina HumanOmniExpressExome-8 BeadChip at the Riken Center for Genomic Medicine, interrogating 964,055 SNPs with coverage of common variants and additional exonic content. All samples passed a low call rate filter (> 0.99). Two unintended duplicates were excluded. An X chromosome heterozygosity estimation identified three genetic males that were removed. To avoid potential population stratification, principal component analysis (PCA) was performed using genotypes of all 628 patients to determine genetic ancestry with the GenABEL R package. 28 A total of 485 patients of European genetic ancestry were identified and confirmed with a second PCA using the EIGENSTRAT method. 29 Samples were excluded if any of the first three principal component vectors were outside two SDs of the mean values for patients self-reporting "White" race and "NonHispanic"/"Unknown" ethnicity, resulting in 478 samples for the primary analysis. SNPs were excluded using the following quality-control filters: minor allele frequency (MAF) < 0.05, deviation from Hardy-Weinberg Equilibrium with P value < 1E-8, call rate < 0.99, and nonautosomal, leaving 574,465 SNPs for analysis. The analysis was further limited to the 468 genetic European patients who had complete data for PFS and all previously identified clinical covariates in the primary analysis from the clinical trial (prior taxane status, hormone receptor status, disease-free interval, and presence of visceral metastases). 27 PFS was defined as the time from registration until the date of the first disease progression or death from any cause, censoring at 50 months posttreatment in absence of an event or at the time of treatment discontinuation for any cause other than progression. To maintain complete data across all loci as required by the elastic net, SNPs with incomplete data were excluded, leaving 493,693 SNPs for analysis. An additional 130 nonEuropean patients with complete data for the final model were reserved to evaluate model prediction.
Statistical analysis
To reduce the number of SNPs remaining in the model by chance alone, 10-fold cross-validation was performed to create a final prediction model (see Figure 5) . Ten initial models were created by subdividing the samples into 10 groups of approximately equal size. For each model, one group of samples was reserved for validation, so that each sample was used in exactly one test set. Each model was developed with the remaining samples as the training set. To reduce the dimensionality in the elastic net regularization, the 1,000 SNPs showing the strongest association with the trait were preselected for each model as follows. A variant-by-variant GWAS, using Cox proportional hazards regression with PFS as the outcome of interest and stratified by treatment arm, was performed on the training data. Regardless of whether a SNP attained genome-wide significance, the 1,000 SNPs with the smallest P values were retained. For each training set, an elastic net Cox proportional hazards model was applied to the top 1,000 SNPs along with previously identified clinical covariates. 27 Both variable selection and regularization to enhance prediction accuracy was performed via elastic net regularization using the glmnet R package. 30, 31 The elastic net model has two tuning parameters, α and λ. 31 An α = 1 corresponds to the LASSO penalty and an α = 0 is the ridge penalty. To balance equally between ridge and LASSO regressionsand both improve prediction by shrinking estimates to reduce overfitting and perform variable selection-a constraint parameter of α = 0.5 was used. Cross-validation determined the optimal value of λ, using a pathwise coordinate descent. Solutions for ̂ were computed for a decreasing sequence of λ, starting with the smallest value for which all ̂ = 0. To account for the randomness in the cross-validation, the model was run 100 times, and the error curves were averaged for each value of λ. The value of λ with the smallest mean cross-validation error was selected as the optimal λ. The AUC of each initial model was calculated using the reserved test data using the Song and Zhou estimator in the survAUC R package. 32 The models created across all 10 training sets were compared, and SNPs remaining in all 10 models were retained. These SNPs were used to create a final model using all genetic European samples. The AUC of this model was calculated using 130 non-European samples from patients with complete data across all covariates using the same estimator described above. A bootstrap method was used to estimate a 95% CI for AUC. All analyses were conducted at the University of California, San Francisco.
